ERBB2 and cancer: To evaluate additional Fc-mediated effector functions, we evaluated the ability of zanidatamab to mediate ADCC and ADCP of HER2-expressing cancer cells using flow cytometry with human PBMCs and PBMC-derived macrophage as effector cells, respectively.